Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nedosiran - Dicerna Pharmaceuticals

Next Previous
Drug Profile

Nedosiran - Dicerna Pharmaceuticals

Alternative Names: DCR PHXC; Nedosiran sodium - Dicerna Pharmaceuticals; Nidosiran; NN-7022; RivflozaTM

Latest Information Update: 04 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dicerna Pharmaceuticals
  • Class Amides; Amino sugars; Drug conjugates; Small interfering RNA; Urologics
  • Mechanism of Action Lactate dehydrogenase 5 expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary hyperoxaluria
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Primary hyperoxaluria type 1
  • Phase III Primary hyperoxaluria

Most Recent Events

  • 02 Oct 2023 Novo Nordisk plans to launch nedosiran for Primary hyperoxaluria type 1 in USA (SC), in early 2024.
  • 29 Sep 2023 Registered for Primary hyperoxaluria type 1 (In children, In adolescents, In adults, In the elderly) in USA (SC) - First global approval
  • 15 Aug 2023 Dicerna Pharmaceuticals initiates an expanded access trial for Primary hyperoxaluria type 1 (In adolescents, In adults, In children, In the elderly) in an undisclosed locations (SC) (NCT05993416)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top